General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies  : Episode 7

Opinion

Video

October 7, 2024

Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis

Author(s):

Karan Lal, DO, MS, FAADHelen T Shin, MD

Key Takeaways

Roflumilast is used for COPD, reducing exacerbations but may cause gastrointestinal side effects.
Apremilast is indicated for psoriatic arthritis and plaque psoriasis, with a favorable safety profile.
Both PDE4 inhibitors modulate inflammatory pathways, but differ in clinical applications and side effect profiles.

Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.

EP: 1.Psychosocial Impact of Plaque Psoriasis in Younger Children

EP: 2.Overview of the Prevalence of Pediatric Plaque Psoriasis

EP: 3.Navigating Treatment Algorithms: Balancing Provider Preferences and Clinical Guidelines

EP: 4.Diagnostic Challenges in the Management of Pediatric Plaque Psoriasis

EP: 5.Adult vs Pediatric Plaque Psoriasis Treatment Challenges

EP: 6.Early Diagnosis and Management, Unmet Needs and Treatment Challenges in Pediatric Plaque Psoriasis

Now Viewing

EP: 7.Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis

EP: 8.Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis

EP: 9.Provider Aspirations for Future Treatments and Clinical Investigations into Pediatric Plaque Psoriasis

Video content above is prompted by the following:

Currently there are two approved PDE4 inhibitors in this category. Could you provide an overview of these systemic treatments, highlighting their key differences and considerations in terms of efficacy and safety?